Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12677805 | 0.84 | ALDH1A1 (0.54) | ALDH1A1GFERKDM4EGPBAR1HPGDS | |
| SCHEMBL1574696 | 0.79 | KDM4E (0.70) | ALDH1A1GFERKDM4EHPGDSL3MBTL1 | |
| SCHEMBL1574753 | 0.79 | ALDH1A1 (0.72) | ALDH1A1GFERKDM4EGPBAR1HPGDS | |
| SCHEMBL1574405 | 0.77 | KDM4E (0.58) | ALDH1A1GFERKDM4EHPGDSL3MBTL1 | |
| SCHEMBL12677808 | 0.75 | ALDH1A1 (0.51) | ALDH1A1GFERKDM4EGPBAR1HPGDS | |
| SCHEMBL1574547 | 0.75 | ALDH1A1 (0.51) | ALDH1A1GFERKDM4EHPGDSL3MBTL1 | |
| SCHEMBL29750685 | 0.74 | HSD17B10 (0.54) | ALDH1A1GFERKDM4EHPGDSL3MBTL1 | |
| SCHEMBL1574486 | 0.74 | HSD17B10 (0.54) | ALDH1A1GFERKDM4EHPGDSL3MBTL1 | |
| SCHEMBL14036445 | 0.74 | HDAC1 (0.56) | ALDH1A1KDM4EHPGDS | |
| SCHEMBL12827022 | 0.73 | ALDH1A1 (0.50) | ALDH1A1GFERKDM4EHPGDSL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | SELL, SELP, SELE | ALDH1A1 528/4885GFER 1627/4885KDM4E 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.